# Predoctoral Training Grant in Pharmacology INCLUDE Down Syndrome Supplement

> **NIH NIH T32** · UNIVERSITY OF COLORADO DENVER · 2022 · $121,779

## Abstract

Abstract:
 The University of Colorado Anschutz Medical Campus (UC/AMC) Pharmacology Graduate
Training Program is currently in its 43rd year of NIGMS funding. The Training Program
distinguishes itself by providing a highly interactive environment in which students obtain a
broadly-based integrative perspective on science and training in the fundamental knowledge
defining pharmacology. The Principal Investigator (PI) for the Training Grant is Dr. Mark
Dell’Acqua, Interim Chair of the Department of Pharmacology. The Training Program Director
and co-PI of the Training Grant is Dr. David Port, who Chairs the Graduate Training Committee
(GTC), which provides the day-to-day oversight for this Training Program. The ~55 members of
the Training Program faculty are drawn from numerous departments within the School of
Medicine and have been recruited to provide broad, multidisciplinary training opportunities in
neuropharmacology, cell signaling, pharmacogenetics, cancer biology,
cardiovascular/pulmonary biology, molecular structure, and bioinformatics. Training Program
faculty are all accomplished, committed researchers and mentors with significant extramural
funding. The sources of students entering the Training Program include direct applicants to the
Program, as well as students who transition from ‘umbrella’ programs (Biomedical Sciences and
Medical Scientist Training Programs). Hallmarks of the Program are a comprehensive didactic
component, 3 laboratory rotations, a strong emphasis on student presentations in seminar
settings, and a wide choice of thesis research options. Career development in the
pharmacological sciences and student initiative are also emphasized. The Training Program
currently has a total of 33 students including 7 students from the MSTP track as well as several
matriculating in from the Biomedical Sciences umbrella program. The competitiveness of the
students for individual national fellowships, high quality publications in peer-reviewed journals
and invitations to participate in national meetings are all measures by which the successful
training of the students is gauged. Retention of our graduates in academic, industry and
government positions is another measure of the success of the Training Program. The Program
continues to thrive and meet the national demands for individuals, trained as pharmacologists,
who are individually astute researchers, can be multidisciplinary research team members, and
also have the breadth of knowledge to plan and communicate effectively across a spectrum of
technologies.
 The current proposal for a renewal of an INCLUDE Down syndrome supplement to the
existing parent Program that will serve to continue to enhance the already robust environment
for training graduate students in areas of scientific enquiry germane to Down syndrome and its
co-occuring conditions. As articulated in the proposal, a number of faculty mentors in the
training program are deeply invested in Down syndrome related research and ...

## Key facts

- **NIH application ID:** 10595386
- **Project number:** 3T32GM007635-44S1
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** MARK L DELL'ACQUA
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $121,779
- **Award type:** 3
- **Project period:** 1978-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10595386

## Citation

> US National Institutes of Health, RePORTER application 10595386, Predoctoral Training Grant in Pharmacology INCLUDE Down Syndrome Supplement (3T32GM007635-44S1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10595386. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*